Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
November 19, 2020 17:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
November 06, 2020 17:01 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 02, 2020 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
August 10, 2020 16:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to...
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
July 29, 2020 16:27 ET
|
Spring Bank Pharmaceuticals, Inc.
Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programsCombined company expected to have at least $40 million in cash prior to...
Spring Bank Advances IV SB 11285 Clinical Program
June 03, 2020 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
- Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1...
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference
May 26, 2020 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 20, 2020 07:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
May 07, 2020 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I...
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
April 02, 2020 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose...